Skip to content

Multiple Sclerosis, Sarcopenia and Respiration

Examination of Sarcopenia and Respiratory Functions in Multiple Sclerosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07152015
Enrollment
40
Registered
2025-09-03
Start date
2025-09-05
Completion date
2025-09-20
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

multiple sclerosis, sarcopenia, inspiratory muscle strength

Brief summary

The goal of this observational study is to evaluate the relationship between respiratory function and sarcopenia in people with multiple sclerosis. The main questions it aims to answer are: Is there a relationship between muscle structure and respiratory muscle strength/pulmonary function in MS patients? Undergo a single session of respiratory muscle strength measurement (e.g., maximal inspiratory pressure \[MIP\], maximal expiratory pressure \[MEP\]) Perform spirometry to assess pulmonary function

Interventions

None listed

Sponsors

Uskudar University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Being diagnosed with MS by a neurologist * Being diagnosed with Sarcopenia * No history of attacks in the last 3 months * Able to walk with and without support (EDSS\<6.5)

Exclusion criteria

* Having concomitant lung and heart disease * Mini Mental score below 24 * Being in pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Forced Vital Capacity1 day (The evaluation will be done one-time)FVC, defined as the total volume of air that can be forcibly exhaled after full inspiration, will be recorded with spirometry using the Cosmed Pony FX device, following ATS guidelines.
Forced Expiratory Volume in 1 second (FEV1)1 day (The evaluation will be done one-time)FEV1, spirometric evaluation of the maximum volume of air exhaled in the first second of a forced breath, will be measured using the Cosmed Pony FX device (Rome, Italy) in accordance with ATS standards.
FEV1/FVC Ratio (%)1 day (The evaluation will be done one-time)The ratio of FEV1 to FVC (FEV1/FVC) will be obtained as an index of airflow limitation. This ratio will be calculated from spirometry values measured with the Cosmed Pony FX device under ATS standards.
Maximal Inspiratory Pressure1 day (The evaluation will be done one-time)MIP, reflecting inspiratory muscle strength, will be assessed through maximal inspiratory efforts against a closed airway, using the Cosmed Pony FX device according to ATS recommendations.
Maximal Expiratory Pressure1 day (The evaluation will be done one-time)MEP, representing expiratory muscle strength, will be determined by maximal expiratory efforts against a closed airway. Measurements will be obtained with the Cosmed Pony FX device (Rome, Italy) according to ATS standards

Secondary

MeasureTime frameDescription
and grip strength measurement1 day (The evaluation will be done one-time)Muscle strength assessment will do by measuring handgrip strength. The measurement is performed with the JAMAR hand dynamometer upon the recommendation of the American Hand Therapists Association.
Skeletal Muscle Index (SMI, kg/m²)1 day (The evaluation will be done one-time)Skeletal Muscle Index (SMI) will be assessed using bioelectrical impedance analysis (BIA). SMI will be calculated as appendicular skeletal muscle mass (kg) divided by height squared (m²). Measurements will be performed once at baseline under standard BIA testing conditions.

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORTuba Kolaylı Çerezci, PhD(c)

Uskudar University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026